-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Bxetowj21OyVgGThJ+ToWP+wjNKjU22qoOUK+yMuqJSctglaZtSTUaP/MAI10sjM +N1w4OoFqvhQvO6b/vlhDQ== 0000950123-96-000565.txt : 19960216 0000950123-96-000565.hdr.sgml : 19960216 ACCESSION NUMBER: 0000950123-96-000565 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19960213 SROS: NONE GROUP MEMBERS: JOHNSON & JOHNSON GROUP MEMBERS: NEUTROGENA CORP SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CELLEGY PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-45279 FILM NUMBER: 96517211 BUSINESS ADDRESS: STREET 1: 371 BEL MARTIN KEYS CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4153826770 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 9085240400 SC 13G 1 SCHEDULE 13G 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cellegy Pharmaceuticals, Inc. ----------------------------------------- (Name of Issuer) Common Stock ----------------------------------------- (Title of Class of Securities) 15115L-10-3 ----------------------------------------- (CUSIP Number) Check the following box if a fee is being paid with this statement [x]. (A fee is not required only if the filing person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on following page(s)) Page 1 of 7 Pages 2 CUSIP NO. 15115L-10-3 13G PAGE 2 OF 7 PAGES 1 NAME OF REPORTING PERSON S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Neutrogena Corporation 95-2221471 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ X ] 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware 5 SOLE VOTING POWER 0 NUMBER OF 6 SHARED VOTING POWER SHARES BENEFICIALLY 475,560 OWNED BY EACH REPORTING 7 SOLE DISPOSITIVE POWER PERSON WITH 0 8 SHARED DISPOSITIVE POWER 475,560 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 475,560 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES * 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 12.61% 12 TYPE OF REPORTING PERSON* CO *SEE INSTRUCTION BEFORE FILLING OUT! 3 CUSIP NO. 15115L-10-3 13G PAGE 3 OF 7 PAGES 1 NAME OF REPORTING PERSON S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Johnson & Johnson 22-1024240 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ X ] 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION New Jersey 5 SOLE VOTING POWER 0 NUMBER OF 6 SHARED VOTING POWER SHARES BENEFICIALLY 475,560 OWNED BY EACH REPORTING 7 SOLE DISPOSITIVE POWER PERSON WITH 0 8 SHARED DISPOSITIVE POWER 475,560 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 475,560 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES * 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 12.61% 12 TYPE OF REPORTING PERSON* CO *SEE INSTRUCTION BEFORE FILLING OUT! 4 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 --------------------------------- SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 --------------------------------- Item 1. (a). Name of Issuer: Cellegy Pharmaceuticals, Inc. (b). Address of Issuer's Principal Executive Offices: 371 Bel Marin Keys Novato, CA 94949 Item 2. (a). Name of Person Filing: Johnson & Johnson Neutrogena Corporation (b). Address of Principal Business Office: One Johnson & Johnson Plaza New Brunswick, NJ 08933 Page 4 of 7 Pages 5 Item 2. (c). Citizenship: Johnson & Johnson - New Jersey Neutrogena Corporation - Delaware (d). Title of Class of Securities: Common Stock (e). CUSIP Number: 15115L-10-3 Item 3. This statement is filed pursuant to Rule by Not applicable Item 4. Ownership. (a). Amount Beneficially Owned Each corporation beneficially owns 475,560 shares (b). Percent of Class: 12.61% (c). Number of Shares as to which each such person has: (i) sole power to vote or to direct the vote 0 (ii) shared power to vote or to direct the vote 475,560 (iii) sole power to dispose or to direct the disposition of 0 (iv) shared power to dispose or to direct the disposition of 475,560 Page 5 of 7 Pages 6 Item 5. Ownership of Five Percent or Less of a Class: Not applicable. Item 6. Ownership of More Than Five Percent on Behalf of Another Person: Not applicable. Item 7. Identification and Classification of Subsidiaries which Acquired the Security Being Reported on by the Parent Holding Company: Not applicable. Item 8. Identification and Classification of Members of the Group: Not applicable. Page 6 of 7 Pages 7 Item 9. Notice of Dissolution of Group: Not applicable. Item 10. Certification: Not applicable. Signature: After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. JOHNSON & JOHNSON By: /s/ James R. Utaski ------------------------ Name/Title: James R. Utaski Vice President NEUTROGENA CORPORATION By: /s/ Clay H. Paterson ------------------------ Name/Title: Clay H. Paterson Secretary Dated: February 13, 1996 Page 7 of 7 Pages -----END PRIVACY-ENHANCED MESSAGE-----